SCHEMBL2345266

SCHEMBL2345266

O=[N+]([O-])c1ccc(CO)cc1O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 2/20 0.58
SNCA P37840 2/20 0.51
MAPT P10636 4/20 0.48
ALDH1A1 P00352 3/20 0.48
POLB P06746 2/20 0.46
HPGD P15428 3/20 0.45
CYP3A4 P08684 2/20 0.45
HSD17B10 Q99714 2/20 0.45
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
RECQL P46063 1/20 0.45
BLM P54132 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
TTR P02766 1/20 0.44
TP53 P04637 2/20 0.44
TSHR P16473 2/20 0.44
MAPK1 P28482 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9198508 0.86 SNCA (0.62) GPR35SNCAMAPTALDH1A1POLB
SCHEMBL1736272 0.85 POLB (0.62) GPR35SNCAMAPTALDH1A1POLB
SCHEMBL515466 0.84 MAPT (0.54) GPR35SNCAMAPTALDH1A1POLB
SCHEMBL30279826 0.83 GPR35 (0.56) GPR35SNCAMAPTALDH1A1POLB
SCHEMBL11328176 0.83 GPR35 (0.56) GPR35SNCAMAPTALDH1A1POLB
SCHEMBL5175273 0.83 GPR35 (0.56) GPR35SNCAMAPTALDH1A1POLB
SCHEMBL4962677 0.83 GPR35 (0.56) GPR35SNCAMAPTALDH1A1POLB
SCHEMBL10680353 0.83 GPR35 (0.56) GPR35SNCAMAPTALDH1A1POLB
SCHEMBL8063487 0.83 GPR35 (0.56) GPR35SNCAMAPTALDH1A1POLB
SCHEMBL15466784 0.81 GPR35 (0.55) GPR35SNCAMAPTALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115947677-B Prodrug compound and preparation method and application thereof 湖南工程学院 2024-07-23 CN claimed
US-12459883-B2 Substituted hydroxystilbene compounds and derivatives synthesis and uses thereof Kynan Duke IP, LLC (US) 2025-11-04 US disclosed
CN-115947677-B Prodrug compound and preparation method and application thereof 湖南工程学院 2024-07-23 CN disclosed
CN-115417859-B Synthesis method of rizatriptan benzoate 陕西师范大学 2024-02-02 CN disclosed
US-11807621-B2 Compounds and compositions for use in treating skin disorders KAMARI PHARMA LTD. (IL) 2023-11-07 US disclosed
US-20230159421-A1 SUBSTITUTED HYDROXYSTILBENE COMPOUNDS AND DERIVATIVES SYNTHESIS AND USES THEREOF Kynan Duke IP, LLC (US) 2023-05-25 US disclosed
CN-115485259-A Substituted hydroxystilbene compounds and derivatives, synthesis and use thereof 凯楠公爵IP有限责任公司 2022-12-16 CN disclosed
CN-113912853-A Self-depolymerizing polymer, nano-particle based on self-depolymerizing polymer and application thereof 中国科学技术大学 2022-01-11 CN disclosed
WO-2021127743-A1 SUBSTITUTED HYDROXYSTILBENE COMPOUNDS AND DERIVATIVES SYNTHESIS AND USES THEREOF Kynan Duke IP, LLC (US) 2021-07-01 WO disclosed
CN-107207444-B Bicyclic compounds 武田药品工业株式会社 2020-07-24 CN disclosed
EP-1163220-A1 TRICYCLIC INDOLE-2-CARBOXYLIC ACID COMPOUND USED AS NMDA RECEPTOR ANTAGONIST SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-12-19 EP disclosed
US-6140041-A Fluorescent dye THE SCRIPPS RESEARCH INSTITUTE (US) 2000-10-31 US disclosed
WO-2000056711-A1 TRICYCLIC INDOLE-2-CARBOXYLIC ACID COMPOUND USED AS NMDA RECEPTOR ANTAGONIST SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2000-09-28 WO disclosed
US-5958673-A Fluorescent dye THE SCRIPPS RESEARCH INSTITUTE (US) 1999-09-28 US disclosed
WO-1999038919-A1 FLUORESCENT DYE NOVARTIS AG (CH) 1999-08-05 WO disclosed
US-5599913-A COMPLEXES HARRIS STEPHEN J (IE) 1997-02-04 US disclosed
WO-1994004483-A1 CHROMOGENIC LIGANDS AND USE THEREOF IN OPTICAL SENSORS HARRIS STEPHEN JOHN (IE) 1994-03-03 WO disclosed
EP-0581464-A1 Ester derivatives and pharmaceutical compositions containing them ZENECA LIMITED (GB) 1994-02-02 EP disclosed
US-5274002-A 1-Oxy- or -thio-2-cycloalkyloxy-4-carboxyalkylene benzene derivatives WARNER-LAMBERT COMPANY (US) 1993-12-28 US disclosed
US-4971959-A Trisubstituted phenyl analogs having activity for congestive heart failure WARNER-LAMBERT COMPANY (US) 1990-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12459883-B2 Substituted hydroxystilbene compounds and derivatives synthesis and uses thereof CYP8B1, HSD11B1, HSD11B2 GPR35 930/4885SNCA 2440/4885MAPT 3957/4885
US-20230159421-A1 SUBSTITUTED HYDROXYSTILBENE COMPOUNDS AND DERIVATIVES SYNTHESIS AND USES THEREOF CYP8B1, HSD11B1, HSD11B2 GPR35 930/4885SNCA 2440/4885MAPT 3957/4885
US-11807621-B2 Compounds and compositions for use in treating skin disorders RDX, HAX1, F12 GPR35 3192/4885SNCA 3740/4885MAPT 3652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.